CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.19 USD
+0.02 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.18 -0.01 (-0.84%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 21 - 40 ( 157 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; CX-904 Ph 1 Data in 1H:24, IND Filings in 4Q:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Private Funding Extends Runway Into 2H25; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; CX-904 in Ph1 Dose Escalation, CX-801 CX-2051 IND in 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ABBV Says No to CX-2029, CX-801 & CX-2051 IND Next in 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Probing into 2023; New CX-2029 Data, Moderna Collaboration
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moderna Alliance Highlights Importance of Masking Technology; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Partnership Enables Further Bi-Specific Development; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financials; Clinical Data Catalysts Approaching; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Preclinical EpCAM ADC Data at World ADC Conference; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M